Free Trial
The Market Does Not Wait. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Steve Lichtman Analyst Performance

Analyst at William Blair

Steve Lichtman is a stock analyst at William Blair in the medical sector, covering 1 publicly traded companies. Over the past year, Steve Lichtman has issued 1 stock ratings, including and buy recommendations. While full access to Steve Lichtman's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Steve Lichtman's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
1 Last 0 Years
Buy Recommendations
100.00% 1 Buy Ratings
Companies Covered
1 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy100.0%1 ratings
Hold0.0%0 ratings
Sell0.0%0 ratings

the majority (100.0%) have been Buy recommendations.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
1 company

Steve Lichtman, an analyst at William Blair, currently covers 1 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
1 company
100.0%

Steve Lichtman of William Blair specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED PRODUCTS
1 company
100.0%

Steve Lichtman's Ratings History at William Blair

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Insulet Corporation stock logo
PODD
Insulet
5/20/2026Initiated Coverage$156.01Outperform